Dopamine transporter gene variation modulates activation of striatum in youth with ADHD

NeuroImage

Volumn 53, Issue 3, 2010, Pages 935-942

  Bédard, Anne Claude ^a   Schulz, Kurt P ^a   Cook, Edwin H ^b   Fan, Jin ^a   Clerkin, Suzanne M ^a   Ivanov, Iliyan ^a   Halperin, Jeffrey M ^a,c   Newcorn, Jeffrey H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE;

3' UNTRANSLATED REGION; ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN REGION; CHILD; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DNA POLYMORPHISM; ETHNICITY; EXON; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; IMAGE ANALYSIS; MALE; PHENOTYPE; PREMOTOR CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVA ANALYSIS; TASK PERFORMANCE; VARIABLE NUMBER OF TANDEM REPEAT;

3' UNTRANSLATED REGIONS; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN MAPPING; CHILD; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77956229944     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.12.041     Document Type: Article

References (71)

1. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Press, Washigton, D.C. 4th ed.
2. Aron A.R., Durston S., Eagle D.M., Logan G.D., Stinear C.M., Stuphorn V. Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition. J. Neurosci.:Off. J. Soc. Neurosci. 2007, 27:11860-11864.
3. Bannon M.J., Michelhaugh S.K., Wang J., Sacchetti P. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur. Neuropsychopharmacol. 2001, 11:449-455.
4. Bertolino A., Blasi G., Latorre V., Rubino V., Rampino A., Sinibaldi L., Caforio G., Petruzzella V., Pizzuti A., Scarabino T., Nardini M., Weinberger D.R., Dallapiccola B. Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J. Neurosci.:Off. J. Soc. Neurosci. 2006, 26:3918-3922.
5. Breese G.R., Duncan G.E., Napier T.C., Bondy S.C., Iorio L.C., Mueller R.A. 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 1987, 240:167-176.
6. Brookes K.J., Neale B.M., Sugden K., Khan N., Asherson P., D'Souza U.M. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2007, 144B:1070-1078.
7. Brown, A.B., Biederman, J., Valera, E.M., Doyle, A.E., Bush, G., Spencer, T., Monuteaux, M.C., Mick, E., Whitfield-Gabrieli, S., Makris, N., Laviolette, P.S., Oscar-Berman, M., Faraone, S.V., Seidman, L.J., 2009. Effect of dopamine transporter gene (SLC6A3) variation on dorsal anterior cingulate function in attention-deficit/hyperactivity disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics.
8. Chikazoe J., Konishi S., Asari T., Jimura K., Miyashita Y. Activation of right inferior frontal gyrus during response inhibition across response modalities. J. Cogn. Neurosci. 2007, 19:69-80.
9. Ciliax B.J., Drash G.W., Staley J.K., Haber S., Mobley C.J., Miller G.W., Mufson E.J., Mash D.C., Levey A.I. Immunocytochemical localization of the dopamine transporter in human brain. J. Comp. Neurol. 1999, 409:38-56.
10. Cook E.H., Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., Leventhal B.L. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 1995, 56:993-998.
11. DuPaul G.J., Power T.J., Anastopoulos A.D., Reid R. ADHD Rating Scale - IV: Checklists, Norms, and Clinical Interpretation 1998, The Guilford Press, New York.
12. Durston S., Thomas K.M., Worden M.S., Yang Y., Casey B.J. The effect of preceding context on inhibition: an event-related fMRI study. NeuroImage 2002, 16:449-453.
13. Durston S., Tottenham N.T., Thomas K.M., Davidson M.C., Eigsti I.M., Yang Y., Ulug A.M., Casey B.J. Differential patterns of striatal activation in young children with and without ADHD. Biol. Psychiatry 2003, 53:871-878.
14. Durston S., Davidson M.C., Tottenham N., Galvan A., Spicer J., Fossella J.A., Casey B.J. A shift from diffuse to focal cortical activity with development. Dev. Sci. 2006, 9:1-8.
15. Durston S., Mulder M., Casey B.J., Ziermans T., van Engeland H. Activation in ventral prefrontal cortex is sensitive to genetic vulnerability for attention-deficit hyperactivity disorder. Biol. Psychiatry 2006, 60:1062-1070.
16. Durston S., Fossella J.A., Mulder M.J., Casey B.J., Ziermans T.B., Vessaz M.N., Van Engeland H. Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47:61-67.
17. Faraone S.V., Khan S.A. Candidate gene studies of attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2006, 67(Suppl. 8):13-20.
18. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:1313-1323.
19. Feron F.J., Hendriksen J.G., van Kroonenburgh M.J., Blom-Coenjaerts C., Kessels A.G., Jolles J., Weber W.E., Vles J.S. Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate. Pediatr. Neurol. 2005, 33:179-183.
20. Franke B., Hoogman M., Arias Vasquez A., Heister J.G., Savelkoul P.J., Naber M., Scheffer H., Kiemeney L.A., Kan C.C., Kooij J.J., Buitelaar J.K. Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1576-1579.
21. Friston K.J., Fletcher P., Josephs O., Holmes A., Rugg M.D., Turner R. Event-related fMRI: characterizing differential responses. NeuroImage 1998, 7:30-40.
22. Fuke S., Suo S., Takahashi N., Koike H., Sasagawa N., Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001, 1:152-156.
23. Ghisi V., Ramsey A.J., Masri B., Gainetdinov R.R., Caron M.G., Salahpour A. Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. Cell. Signal. 2009, 21:87-94.
24. Gizer I.R., Ficks C., Waldman I.D. Candidate gene studies of ADHD: a meta-analytic review. Hum. Genet. 2009, 126:51-90.
25. Gruber R., Joober R., Grizenko N., Leventhal B.L., Cook E.H., Stein M.A. Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2009, 19:233-239.
26. Halperin, J.M., Bedard, A.V., Berwid, O.G., in press. Attention deficit hyperactivity disorder: a lifespan synthesis. In: Hunter, S.J., Donders, J. (Eds.), Principles and Practice of Lifespan Developmental Neuropsychology. Cambridge University Press, United Kingdom.
27. Hawi Z., Kent L., Hill M., Anney R.J., Brookes K.J., Barry E., Franke B., Banaschewski T., Buitelaar J., Ebstein R., Miranda A., Oades R.D., Roeyers H., Rothenberger A., Sergeant J., Sonuga-Barke E., Steinhausen H.C., Faraone S.V., Asherson P., Gill M. ADHD and DAT1: further evidence of paternal over-transmission of risk alleles and haplotype. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 153B(1):97-102.
28. Hayasaka S., Phan K.L., Liberzon I., Worsley K.J., Nichols T.E. Nonstationary cluster-size inference with random field and permutation methods. NeuroImage 2004, 22:676-687.
29. Heinz A., Goldman D., Jones D.W., Palmour R., Hommer D., Gorey J.G., Lee K.S., Linnoila M., Weinberger D.R. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000, 22:133-139.
30. Hermens D.F., Rowe D.L., Gordon E., Williams L.M. Integrative neuroscience approach to predict ADHD stimulant response. Expert Rev. Neurother. 2006, 6:753-763.
31. Hoover J.E., Strick P.L. Multiple output channels in the basal ganglia. Science 1993, 259:819-821.
32. Hu X.T., Wachtel S.R., Galloway M.P., White F.J. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. J. Neurosci.:Off. J. Soc. Neurosci. 1990, 10:2318-2329.
33. Jacobsen L.K., Staley J.K., Zoghbi S.S., Seibyl J.P., Kosten T.R., Innis R.B., Gelernter J. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am. J. Psychiatry 2000, 157:1700-1703.
34. Johansson S., Halleland H., Halmoy A., Jacobsen K.K., Landaas E.T., Dramsdahl M., Fasmer O.B., Bergsholm P., Lundervold A.J., Gillberg C., Hugdahl K., Knappskog P.M., Haavik J. Genetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5-microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1470-1475.
35. Johnstone T., Ores Walsh K.S., Greischar L.L., Alexander A.L., Fox A.S., Davidson R.J., Oakes T.R. Motion correction and the use of motion covariates in multiple-subject fMRI analysis. Hum. Brain Mapp. 2006, 27:779-788.
36. Joober R., Grizenko N., Sengupta S., Amor L.B., Schmitz N., Schwartz G., Karama S., Lageix P., Fathalli F., Torkaman-Zehi A., Ter Stepanian M. Dopamine transporter 3'-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 2007, 32:1370-1376.
37. Kang A.M., Palmatier M.A., Kidd K.K. Global variation of a 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene (SLC6A3). Biol. Psychiatry 1999, 46:151-160.
38. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., Williamson D., Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:980-988.
39. Kawarai T., Kawakami H., Yamamura Y., Nakamura S. Structure and organization of the gene encoding human dopamine transporter. Gene 1997, 195:11-18.
40. Kelly R.M., Strick P.L. Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog. Brain Res. 2004, 143:449-459.
41. Kirley A., Lowe N., Hawi Z., Mullins C., Daly G., Waldman I., McCarron M., O'Donnell D., Fitzgerald M., Gill M. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 121B:50-54.
42. Krause J., Dresel S.H., Krause K.H., La Fougere C., Zill P., Ackenheil M. Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele. World J. Biol. Psychiatry 2006, 7:152-157.
43. Langleben D.D., Acton P.D., Austin G., Elman I., Krikorian G., Monterosso J.R., Portnoy O., Ridlehuber H.W., Strauss H.W. Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. J. Nucl. Med. 2002, 43:1624-1629.
44. Langley K., Turic D., Peirce T.R., Mills S., Van Den Bree M.B., Owen M.J., O'Donovan M.C., Thapar A. No support for association between the dopamine transporter (DAT1) gene and ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 139B:7-10.
45. Lewis D.A., Melchitzky D.S., Sesack S.R., Whitehead R.E., Auh S., Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J. Comp. Neurol. 2001, 432:119-136.
46. Lott D.C., Kim S.J., Cook E.H., de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005, 30:602-609.
47. Martinez D., Gelernter J., Abi-Dargham A., van Dyck C.H., Kegeles L., Innis R.B., Laruelle M. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001, 24:553-560.
48. Mill J., Asherson P., Browes C., D'Souza U., Craig I. Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am. J. Med. Genet. 2002, 114:975-979.
49. Plomp E., van Engeland H., Durston S. Understanding genes, environment, and their interaction in attention-deficit hyperactivity disorder: is there a role for neuroimaging?. Neuroscience 2009, 164(1):230-240.
50. Prata D.P., Mechelli A., Picchioni M.M., Fu C.H., Toulopoulou T., Bramon E., Walshe M., Murray R.M., Collier D.A., McGuire P. Altered effect of dopamine transporter 3'UTR VNTR genotype on prefrontal and striatal function in schizophrenia. Arch. Gen. Psychiatry 2009, 66:1162-1172.
51. Rebec G.V. Real-time assessments of dopamine function during behavior: single-unit recording, iontophoresis, and fast-scan cyclic voltammetry in awake, unrestrained rats. Alcohol Clin. Exp. Res. 1998, 22:32-40.
52. Roman T., Szobot C., Martins S., Biederman J., Rohde L.A., Hutz M.H. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 2002, 12:497-499.
53. Rubia K., Smith A.B., Brammer M.J., Toone B., Taylor E. Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am. J. Psychiatry 2005, 162:1067-1075.
54. Sakagami M., Tsutsui K., Lauwereyns J., Koizumi M., Kobayashi S., Hikosaka O. A code for behavioral inhibition on the basis of color, but not motion, in ventrolateral prefrontal cortex of macaque monkey. J. Neurosci. 2001, 21:4801-4808.
55. Schneider W., Eschman A., Zuccolatto A. E-Prime User's Guide 2002, Psychology Software Tools, Inc., Pittsburgh, PA.
56. Schulz K.P., Fan J., Tang C.Y., Newcorn J.H., Buchsbaum M.S., Cheung A.M., Halperin J.M. Response inhibition in adolescents diagnosed with attention deficit hyperactivity disorder during childhood: an event-related FMRI study. Am. J. Psychiatry 2004, 161:1650-1657.
57. Schulz K.P., Clerkin S.M., Halperin J.M., Newcorn J.H., Tang C.Y., Fan J. Dissociable neural effects of stimulus valence and preceding context during the inhibition of responses to emotional faces. Hum. Brain Mapp. 2009, 30(9):2821-2833.
58. Skounti M., Philalithis A., Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur. J. Pediatr. 2007, 166:117-123.
59. Smith Y., Kieval J.Z. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci. 2000, 23:S28-33.
60. Stein M.A., Waldman I.D., Sarampote C.S., Seymour K.E., Robb A.S., Conlon C., Kim S.J., Cook E.H. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005, 30:1374-1382.
61. Szobot C., Roman T., Renato C., Acton P., Hutz M., Rohde L.A. Brain perfusion and dopaminergic genes in boys with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. Part B 2005, 132B:53-58.
62. Talairach J., Tournoux M. Co-planar Stereotaxic Atlas of the Human Brain 1988, Thieme Medical, New York.
63. Tomasi D., Volkow N.D., Wang R., Telang F., Wang G.J., Chang L., Ernst T., Fowler J.S. Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. PLoS One 2009, 4:e6102.
64. van Dyck C.H., Malison R.T., Jacobsen L.K., Seibyl J.P., Staley J.K., Laruelle M., Baldwin R.M., Innis R.B., Gelernter J. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J. Nucl. Med. 2005, 46:745-751.
65. Vandenbergh D.J., Persico A.M., Hawkins A.L., Griffin C.A., Li X., Jabs E.W., Uhl G.R. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992, 14:1104-1106.
66. VanNess S.H., Owens M.J., Kilts C.D. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 2005, 6:55.
67. Volkow N.D., Wang G.J., Newcorn J., Telang F., Solanto M.V., Fowler J.S., Logan J., Ma Y., Schulz K., Pradhan K., Wong C., Swanson J.M. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 2007, 64:932-940.
68. Winsberg B.G., Comings D.E. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child Adolesc. Psych. 1999, 38:1474-1477.
69. Wu N., Cepeda C., Zhuang X., Levine M.S. Altered corticostriatal neurotransmission and modulation in dopamine transporter knock-down mice. J. Neurophysiol. 2007, 98:423-432.
70. Yang B., Chan R.C., Jing J., Li T., Sham P., Chen R.Y. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:541-550.
71. Zhu J., Reith M.E. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol. Disord. Drug Targets 2008, 7:393-409.